September 15, 2023 06:41 AM EDTUpdated 08:55 AM

Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Lei Lei Wu

News Reporter

Phil Vickers started last week as president and CEO of Solu Therapeutics, a Longwood Fund startup developing small molecule-antibody chimeras. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Lei Lei Wu

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Amgen names Stanford geneticist and biotech founder to CSO post

Caltech spinout debuts with AI-driven 'mirror peptide' platform

Are programs with compounded GLP-1s safe for your population?

Phil Vick­ers talks new role as head of Long­wood’s Solu af­ter Faze shut­down; Re­gen­eron CFO to re­tire in Feb­ru­ary

Copy Chief

Editor

News Reporter

Sign up to read this article for free.

Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February